JC03 Rec'd PCT/PTO 1 2 OCT 2007

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 2-2005)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

INTERNATIONAL FILING DATE

ATTORNEY'S DOCKET NUMBER PB60212-2USW

PRIORITY DATE CLAIMED

U.S. ABPLICATION NO Alf Janown, see 37 CFR 1.5)

April 17, 2003

	PCT/EP04/004122				
_					

INTERNATIONAL APPLICATION NO. April 16, 2004

TITLE OF INVENTION ombinations of Paroxetine and 4-(S)-(4-Acetyl-Piperazin-1-YL)-2-(R)-(4-Fluoro-2-Methyl-Phenyl)- Piperidine-1-Carboxylic Acid

		T(S) FOR DO/EO/US ergio				
Applic	ant h	erewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
1.	\boxtimes	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.				
2.		This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.				
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.				
4.	×	The US has been elected (Article 31).				
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))				
		a. \square is attached hereto (required only if not communicated by the International Bureau).				
		b. 🛛 has been communicated by the International Bureau.				
		c. \square is not required, as the application was filed in the United States Receiving Office (RO/US).				
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).				
		a. is attached hereto.				
		b. has been previously submitted under 35 U.S.C. 154(d)(4).				
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))				
		a. are attached hereto (required only if not communicated by the International Bureau).				
		b. \square have been communicated by the International Bureau.				
		c. \square have not been made; however, the time limit for making such amendments has NOT expired.				
		d. 🖾 have not been made and will not be made.				
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).				
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).				
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).				
11.		A copy of the International Preliminary Examination Report (PCT/IPEA/409).				
12.	\boxtimes	A copy of the International Search Report (PCT/ISA/210).				
ite	ems 1	3 to 23 below concern document(s) or information included:				
13.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.				
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.				
15.	\boxtimes	A FIRST preliminary amendment.				
16.		A SECOND or SUBSEQUENT preliminary amendment.				
17.		A substitute specification.				
18.		A power of attorney and/or change of address letter.				
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.				
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).				
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).				
22.	X	Express Mail Label No. EV 332063875 US				
23.	\boxtimes	Other items or information:				
		a) PCT Cover Page				

ron Ber'd PCT/PTO 12 OCT ZUU:

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO: (If known, 1596 37 GPR 1.5) INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER PCT/EP04/004122 PB60212-2USW The following fees are submitted: **CALCULATIONS** PTO USE \$300 \$300.00 Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4). \$100 \$200.00 \$200 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to \$100 International Search Report prepared and provided to the Office \$400 \$500 \$400.00 TOTAL OF 24, 25 and 26 = \$900.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. **Total Sheets** Number of each additional 50 or Extra Sheets RATE fraction thereof (round up to a whole -100 =/50 = \$250.00 \$ \$0.00 Surcharge of \$130.00 for furnishing the oath or declaration later than months from the \$ earliest claimed priority date (37 CFR 1.492(e)). CLAIMS NUMBER FILED NUMBER EXTRA RATE Total claims 17 - 20 = \$50.00 \$ \$0.00 х Independent claims 2 0 - 3 = \$200.00 \$0.00 MULTIPLE DEPENDENT CLAIMS (if applicable) \$360.00 \$0.00 **TOTAL OF ABOVE CALCULATIONS =** \$900.00 Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are \$0.00 reduced by 1/2. SUBTOTAL = \$900.00 Processing fee of \$130.00 for furnishing the English translation later than 30 months from \$ \$0.00 the earliest claimed priority date (37 CFR 1.492(f)). **TOTAL NATIONAL FEE =** \$ \$900.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property \$0.00 TOTAL FEES ENCLOSED = \$900.00 Amount to be \$ Amount to be \$ a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 07-1392 \$900.00 in the amount of to cover the above fees. A duplicate copy of this sheet is enclosed. c. 🛮 The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1392 . A duplicate copy of this sheet is enclosed. d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status SEND ALL CORRESPONDENCE TO: SIGNATURE Lorie Ann Morgan 23347 NAME 38,181 REGISTRATION NUMBER

		JC20 Rec'd PCT	<u>//PTO 120</u>	CT 2005
CERTIFICATE O		ocket No. 212-2USW		
O Application 7 1 To Be Assigned	Filing Date Concurrently Herewith	Examiner	Customer No. 23347	Group Art Unit
r thei initie.	tions of Paroxetine and 4-(Se-1-Carboxylic Acid '1-(R)- n and/or Anxiety	S)-(4-Acetyl-Piperazin-1-YL)-2-(R)-(4-F -(3,5-BIS-Trifluoromethyl-Phenyl)-Ethy	Fluoro-2-Methyl- yl!Methylamide I	Phenyl)- For Treatment of
I hereby certify that f	the following corresponder	:nce:		
Transmittal of Nation	onal Phase Application w/ac	ccompanying papers		
is being deposited w		dentify type of correspondence) stal Service "Express Mail Post Office	to Addressee" s	enrice under 37
CFR 1.10 in an enve	elope addressed to: Comn	missioner for Patents, P.O. Box 1450,		
~	ctober 12, 200			
		Valerie L.	. Phillips	
		(Typed or Printed Name of Person Valerie L. Me	ellen	'ence)
		(Signature of Person Mailing EV3320	163875U	z)
	٠			